DRKS00032670招募中不适用
Registry of the European Mantle Cell Lymphoma Network - EMCL Registry
niversitätsmedizin der Johannes Gutenberg-Universität Mainz0 个研究点目标入组 100,000 人开始时间: 2023年10月19日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 100,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •Mantle cell lymphoma
- •Informed consent with the exception of deceased patients
排除标准
- •Lymphoma other than MC
研究者
相似试验
招募中
不适用
German Registry for Marginal Zone Lymphoma and Follicular LymphomaFollicular lymphomaC83C82Non-follicular lymphomaDRKS00021517niversitätsklinikum Ulm1,500
进行中（未招募）
不适用
Master protocol for mantle cell lymphomaA multicenter phase II trial testingGemcitabine for the treatment of patients with newlydiagnosed, relapsed or chemotherapy resistantmantle cell lymphomaProtocol SAKK 36/03patients with newlydiagnosed, relapsed or chemotherapy resistant mantle cell lymphomaMedDRA version: 6.1Level: HLGTClassification code 10025323EUCTR2004-002860-43-ITSIAK
进行中（未招募）
不适用
Master protocol for mantle cell lymphoma A multicenter stratified phase II trial testing Everolimus (RAD001) for the treatment of patients with newly diagnosed and relapsed or therapy resistant mantle cell lymphoma - NDmantle cell lymphoma patientsMedDRA version: 9.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaMedDRA version: 9.1Level: LLTClassification code 10026801Term: Mantle cell lymphoma refractoryMedDRA version: 9.1Level: LLTClassification code 10026800Term: Mantle cell lymphoma recurrentEUCTR2007-001108-19-ITSAKK - GRUPPO SVIZZERO DI RICERCA CLINICA SUL CANCRO58
进行中（未招募）
不适用
Master protocol for mantle cell lymphoma. A multicenter phase II trial testing Everolimus ( RAD001) for the treatment of patients with relapsed or thérapy resistant mantle cell lymphoma. Protocol SAKK 36/06Traitement des lymphomes du manteau en deuxième ou troisième ligne (1ère ou 2nd rechute)MedDRA version: 9.1Level: LLTClassification code 10061275Term: Mantle cell lymphomaEUCTR2007-001108-19-FRSAKK35
已完成
2 期
Study to Assess Effect of Oral Venetoclax Tablet in Combination With Oral Ibrutinib Capsule on Best Overall Response of Complete Response in Adult Japanese Participants With Relapsed/Refractory Mantle Cell LymphomaMantle Cell Lymphoma (MCL)NCT04477486AbbVie13